Publication at First Faculty of Medicine, Third Faculty of Medicine |
2014
Abstract
Empagliflozin is a new oral hypoglycaemic agent for the treatment of type 2 diabetes mellitus. Its mechanism of action consists in the inhibition of sodium/glucose cotransporter 2 (SGLT2), resulting in glycosuria and reduction of glycaemia.
In clinical trials, administration of empagliflozin resulted in reduced glycated haemoglobin levels both in monotherapy and in combination with metformin, sulfonylureas, pioglitazone and insulin, and empagliflozin thus represents an effective drug especially for combination treatment of diabetes.